Published on
November 7, 2024
- 13:00 GMT
Neurizon Therapeutics Teams Up with GenieUs Genomics to Leverage Cutting-Edge Genomic Profiling in NUZ-001 Phase 1 Trial
Neurizon partners with GenieUs for the Phase 1 trial, using genomic profiling to enhance patient stratification and deepen therapeutic insights. SYDNEY, AUSTRALIA, November 7, 2024 /EINPresswire.com/ -- GenieUs Genomics (“GenieUs”) is excited to provide advanced genomic analysis for Neurizon Therapeutics Limited’s (“Neurizon”; ASX:NUZ; ASX:NUZOA) Phase 1 clinical trial of monepantel, now known as NUZ-001, marking an important step in understanding the genetic landscape of ALS patients. Neurizon is a …
Distribution channels:
Banking, Finance & Investment Industry, Companies
...
